INTRODUCTION
Recent advances in molecular and cellular cancer biology have resulted in the identification of critical molecular tumor targets involved in the different phases of tumor growth and spreading. This knowledge has boosted the rational design of novel drugs, especially monoclonal antibodies and tyrosine kinase inhibitors. However, broad application of these targeted therapies to treat brain tumors has lagged behind in daily clinical practice. By using molecular positron emission tomography (PET) imaging, target expression, bio-distribution can be studied concurrently in a relatively non-invasive manner. It potentially allows the identification of those patients who may, or may not, benefit from targeted therapy.
A disease that may benefit from molecular imaging is diffuse intrinsic pontine glioma (DIPG), a childhood malignancy located in the brainstem. In the past 40 years the outcome of patients with DIPG has remained unchanged, with less than 10% of the patients being alive two years from diagnosis 88, 89 . Given the lack of gadolinium uptake on MRI in DIPG tumors 11, 15 , it is plausible that the blood brain barrier (BBB) in DIPG often remains intact which might explain the resistance to systemic chemotherapy in these patients.
A well-studied drug target in gliomas is the vascular endothelial growth factor (VEGF), a signal protein stimulating angiogenesis and increasing vessel permeability 209 .
Overexpression of VEGF-A, its receptor VEGFR2, or both, have been implicated as poor prognostic markers in various clinical studies 209, 210 . Bevacizumab is a recombinant humanized monoclonal antibody that selectively binds with high affinity to all isoforms of human VEGF-A, and neutralizes their biologic activity 209, 211 . Studies in adult patients with recurrent high grade gliomas (HGG) reported high radiological response rates with bevacizumab treatment [211] [212] [213] but recently two large phase III randomized studies showed no improvement in overall survival with bevacizumab treatment in an upfront setting [214] [215] [216] . Bevacizumab has been studied in a number of non-randomized trials in pediatric brain tumor patients. Efficacy in these trials has been variable, with a subset of patients showing clear radiological and/or clinical improvement 217, 218 . The role of bevacizumab in the treatment of DIPG patients is even less clear, but is currently studied in several trials [219] [220] [221] [222] , (NCT00890786 and NCT01182350; clinicaltrials.gov; NTR2391 Trialregister.nl) . 
MATERIALS AND METHODS

VEGF-A and VEGFR2 mRNA expression profiles
VEGF-A and VEGFR2 (KDR) mRNA expression in DIPG (n=27) and pediatric high grade glioma (pHGG) (n=53) were determined in silico, using publicly available datasets, and compared to a dataset of non-malignant brain tissue (n=44), low grade brainstem glioma (n= 6) and adult HGG (n=284). These datasets include tumor material from biopsy, resection and autopsy (DIPG). Differences were analysed by two way ANOVA and a p < 0.01 was considered significant. As a validation of these findings, VEGF associated gene expression was studied in normal brain, low grade brainstem glioma (LG-BSG), DIPG and GBM by creating a heat map using K-means clustering. All expression analyses were performed using R2, a web-based microarray analysis and visualization platform (http:// r2.amc.nl).
Immunohistochemistry and in situ hybridization
Formalin-fixed paraffin-embedded slides were sectioned from xenograft tumors and brain tissue and subjected to immunohistochemical (IHC) staining. Briefly, after deparaffinization and heat induced antigen retrieval, sections were incubated with primary mouse anti-Ki67 antibodies (clone MIB-1, DAKO) overnight at 4°C. Thereafter slides were washed and incubated with HRP-conjugated EnVision (DAKO) and subsequently stained by DAB with hematoxylin counterstaining.
For in situ hybridization (ISH), tumors were cut in 5 µm slices and incubated with VEGF probes against the human VEGF coding sequence using a previously described protocol 223 . Samples were evaluated by microscopy with a Zeiss Axioskip microscope (HBO100W/Z), equipped with a Canon digital camera and imaging software (Canon PowerShot A640, Canon Utilities, ZoomBrowser Ex. 5.7, Canon Inc., Tokyo, Japan).
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Labeling and quality control of 89Zr-bevacizumab
Bevacizumab was labeled with zirconium-89 using N-succinyl-desferrioxamine (N-sucDf) as described previously 224 . In short: the chelator, desferrioxamine, was succinylated to N-suc-Df. Next, the hydroxamate groups were blocked with iron and the succinyl group was activated as its TFP-ester (Fe-N-suc-Df-TFP ester). Bevacizumab (6 mg/ mL) was reacted with two equivalents of Fe-N-suc-Df-TFP ester at pH 9 for 30 min at room temperature. Hereafter, iron was removed at pH 4.2-4.5 with an excess of Zr-N-suc-Dfbevacizumab was purified by PD10 using 5 mg/mL gentisic acid in 0.9% NaCl (pH 4.9-5.4) as the mobile phase.
Radiochemical purity and antibody integrity were determined using instant thin-layer chromatography (iTLC), high-performance liquid chromatography (HPLC) and sodium dodecylsulfate-polyacrylamide gel electrophoresis followed by phosphor imager analysis. For analysis of immunoreactivity an ELISA based assay was used. iTLC analysis of 89 Zr-bevacizumab was performed on TEC control chromatography strips (Biodex). As the mobile phase, citrate buffer (20 mmol/L, pH 5.0) containing 10% acetonitrile was used. HPLC analyses of bevacizumab modification and radiolabeling were performed using a Jasco HPLC system equipped with a Superdex TM 200 10/30 GL size exclusion column (GE healthcare Life sciences) using a mixture of 0.05 M sodium phosphate, 0.15 M sodium chloride (pH 6.8) and 0.01 M NaN 3 as the eluent at a flow rate of 0.5 mL/ min. The radioactivity of the eluate was monitored using an inline NaI(Tl) radiodetector (RaytestSockett).
Cell lines and animal models
Animal experiments were performed in accordance with the European Community , the U251 glioma cell line from ATCC. All cell lines were transduced in our laboratory to express firefly luciferase (FLUC) and/or mCherry 225, 226 . Cell lines were mycoplasm negative and were authenticated by STR-analysis modified from De Weger et al. 
PET imaging and ex vivo analysis
The distribution of 89 Zr-bevacizumab was determined 72 hours (ex vivo only) or 96 hours (PET followed by ex vivo analysis) after administration, as a minimum of 72 hours interval between injection and scanning has previously been shown to achieve optimal tumor-to-nontumor ratios 
Magnetic Resonance Imaging (MRI)
Mice with representative HSJD-DIPG-007-FLUC or U251-FM tumors were selected for MRI based on the intensity of the bioluminescence signal. Gadolinium (750 µmol, Dotarem) was administered i.v. immediately before imaging. Mice were anesthetized by isoflurane inhalation anaesthesia (1.5 L 0 2 /minute and 2.5% isoflurane), placed in a preclinical PET-MRI system (Nanoscan system, MEDISO, Budapest, Hungary) and T1 and T2 weighed images with gadolinium contast were acquired. MRI images were analyzed using MIPAV software (Medical Image Processing, Analysis, and Visualization, version 7.2.0) .
Ex vivo analysis
Immediately after PET imaging, animals were sacrificed for ex vivo tissue distribution analysis. Blood, urine, tumor and various tissues were excised, rinsed in PBS to remove 
In situ-hybridization of VEGF
To determine whether the differences in (Figures 6c,d) . In HSJD-DIPG-007-FLUC and U251FM tumors, VEGF mRNA expression was not detectable in striatal and pontine gliomas. The subcutaneous tumors were too small to adequately perform VEGF ISH and therefore no conclusions could be drawn regarding VEGF expression in these s.c. tumors.
Magnetic Resonance Imaging
To visualize disruption of the blood-brain-barrier, mice with HSJD-DIPG-007-FLUC and U251-FM intracranial tumors were imaged by MRI after intravenous administration of gadolinium. In the diff usely growing HSJD-DIPG-007-FLUC tumor, gadolinium enhancement on T1 weighed images was limited (Figure 7a , arrow), whereas gadolinium enhancement was clearly visible in the U251-FM tumor (Figure 7c, arrow) . On T2 weighed images, tumors were not clearly visible (Figures 7b, d ; arrow). originating from the same cell line, confirms that the orthotopic microenvironment and the resulting growth pattern significantly influence gene expression in glioma cells, a phenomenon that has been described previously (19, 20) . Moreover, it has been shown that in GBM, VEGF is predominantly overexpressed in hypoxic, perinecrotic cells 233, 234 .
Indeed, in our study the VEGF expression in subcutaneous E98FM tumors was especially present around areas of necrosis, whereas in intracranial E98FM tumors necrosis and VEGF expression were lacking and this also coincided with lack of bevacizimab uptake studied ex vivo and by PET. Of note, bevacizumab does not bind to murine VEGF-A 131 | Bevacizumab uptake in preclinical brain tumor models angiogenesis we consider it unlikely that stromal cell-derived mouse VEGF-A plays an important role in this particular xenograft model.
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In contrast to our preclinical findings, the in silico analysis that we performed in this study, indicates that human DIPG tumors have relatively high expression levels of VEGF mRNA.
However, the majority of tumors (23 out of 27) used for the microarray experiments were collected post-mortem 92,101 and therefore these samples represent the end-stage of the disease, and are post-radiation therapy. In the end-stage of the disease, DIPG is known to have necrotic areas with microvascular proliferations and blood-brain barrier disruption, compatible with the histology of a GBM, which is associated with high VEGF expression.
Although the numbers are low, it is important to point out that VEGF-A expression levels in samples obtained pre-treatment were low compared to expression in post-mortem/ end-stage samples (supplemental Figure 2) . In addition, biopsy samples that were included in the analysis are frequently directed at contrast-enhancing regions, and this 'biased sampling' may well lead to overestimation of the role of VEGF in the tumor as a whole. We are currently studying the differences in VEGF-A expression in autopsyderived DIPG tissue between the perinecrotic areas and the more diffusely growing tumor parts without necrosis.
Experimental and clinical research in both adult and pediatric high grade glioma and DIPG has suggested that there is a complex relation between a histologically diffuse growth pattern of braintumors, VEGF expression and availability and BBB integrity 163, 223, [236] [237] [238] [239] . . The data presented suggest that no adequate uptake of bevacizumab will occur in diffusely growing gliomas, which present with BBB disruption but without drastically increased VEGF expression. Therefore we suggest that bevacizumab treatment is only justified if targeting of VEGF by bevacizumab has been visualized by immuno-PET scan.
We aim to confirm this hypothesis in a clinical PET study with DIPG patients.
Future directions
This study underlies the importance of using strong biological and biodistributional rationale before using any therapy in any patient. Following the results of this study, we developed a molecular drug imaging trial with 
